Optimization of Thromboprophylaxis Use in Hospitalized Pediatric Patients Through Implementation of a Venous Thromboembolism Risk Assessment Tool
- PMID: 38130498
- PMCID: PMC10731931
- DOI: 10.5863/1551-6776-28.5.452
Optimization of Thromboprophylaxis Use in Hospitalized Pediatric Patients Through Implementation of a Venous Thromboembolism Risk Assessment Tool
Abstract
Objective: Venous thromboembolism (VTE) is a leading cause of hospital-acquired morbidity for pediatric patients. Pharmacological thromboprophylaxis increases the risk of adverse events such as bleeding complications. There exists a need for a universal VTE risk assessment tool to aid in thromboprophylaxis prescribing while minimizing the risk of adverse events. The objective of this study is to investigate if implementation of a VTE risk assessment tool is associated with a change in the rate of thromboprophylaxis prescribing.
Methods: This retrospective study evaluated the change in thromboprophylaxis prescribing pre and post implementation of a VTE risk assessment tool. Patients were excluded if they were pregnant, diagnosed with VTE ≤48 hours of admission, presented with VTE symptoms, or if they were diagnosed with multisystem inflammatory syndrome in children (MIS-C) or coronavirus disease (COVID-19).
Results: A total of 186 pediatric patients were included in this study. Thromboprophylaxis was prescribed in 16/93 (17.12%) and 75/93 (80.6%) patients in the pre- and post-implementation group, respectively (95% CI, 0.523-0.745; p < 0.001). No VTE events occurred in either group. Bleeding complications occurred in 3.2% and 7.5% of patients in the pre- and post-implementation groups, respectively. The risk tool was used in 80.6% of patients; providers used the tool correctly in 48% of patients and incorrectly in 52% of patients.
Conclusion: Implementation of a VTE risk assessment tool was associated with a statistically significant change in the rate of thromboprophylaxis prescribing. Incorrect use may be minimized by providing provider reeducation and making modifications to the order set.
Keywords: anticoagulants; pediatrics; pharmacy; retrospective studies; risk assessment; risk factors; venous thromboembolism.
Copyright. Pediatric Pharmacy Association. All rights reserved. For permissions, email: membership@pediatricpharmacy.org.
Similar articles
-
Optimizing pharmacologic thromboprophylaxis use in pediatric orthopedic surgical patients through implementation of a perioperative venous thromboembolism risk screening tool.Pediatr Blood Cancer. 2021 Feb;68(2):e28803. doi: 10.1002/pbc.28803. Epub 2020 Nov 21. Pediatr Blood Cancer. 2021. PMID: 33219749
-
Incorrect use of thromboprophylaxis for venous thromboembolism in medical and surgical patients: results of a multicentric, observational and cross-sectional study in Brazil.J Thromb Haemost. 2006 Jun;4(6):1266-70. doi: 10.1111/j.1538-7836.2006.01981.x. J Thromb Haemost. 2006. PMID: 16706970
-
Evaluation of the Quality and Safety of Venous Thromboembolism Prophylaxis Among Gastroenterology Inpatients at a Tertiary Hospital in Australia.Hosp Pharm. 2023 Dec;58(6):595-604. doi: 10.1177/00185787231172385. Epub 2023 May 20. Hosp Pharm. 2023. PMID: 38560547 Free PMC article.
-
Consensus-based clinical recommendations and research priorities for anticoagulant thromboprophylaxis in children hospitalized for COVID-19-related illness.J Thromb Haemost. 2020 Nov;18(11):3099-3105. doi: 10.1111/jth.15073. J Thromb Haemost. 2020. PMID: 33174388 Free PMC article. Review.
-
Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.Clin Ther. 2009 Jun;31(6):1129-41. doi: 10.1016/j.clinthera.2009.06.002. Clin Ther. 2009. PMID: 19695383 Review.
References
-
- Park MY, Fletcher JP, Hoffmann C et al. Prevention of venous thromboembolism through the implementation of a risk assessment tool: a comparative study in medical and surgical patients. Int Angiol . 2018;37((5)):411–418. - PubMed
LinkOut - more resources
Full Text Sources